Welltower (WELL) Q3 2026 Earnings Call Transcript

Welltower reported Q3 revenue of $3.72 billion, up 38% year over year, and normalized FFO of $1.67 per diluted share, up 24.6%; it raised the midpoint of full-year normalized FFO guidance by $0.10 to $6.50 per share. SHOP same-store NOI grew 21%, while portfolio occupancy gains and 5.3% RevPOR growth supported margin expansion; year-to-date investment activity reached $21 billion. Management also warned that higher rates, inflation and geopolitical volatility are pressuring asset owners, with about $8 billion of U.S. senior housing debt maturing in 2026 and annual maturities rising to $10 billion–$12 billion in 2027–28.

Analysis

The key quality-of-growth question is whether operating gains can keep outrunning the capital required to buy and lease up new assets. Management’s guidance increase was driven more by investment/financing activity than by SHOP operations, while substantial equity and OP-unit funding makes per-share accretion—not acquisition volume—the test. Recent low-occupancy purchases may offer upside, but add lease-up, operator-transition and near-term cash-flow risk; they should not be valued like stabilized same-store communities.

A higher-for-longer rate environment cuts both ways. Refinancing pressure could create attractive buying opportunities for a well-capitalized buyer, but can also widen cap rates, depress asset values and make external growth less accretive. The clearest operating upside is pricing at established, highly occupied properties: incremental rate gains should carry stronger flow-through than occupancy gains. The counterweight is product-market fit: premium locations may retain pricing power while mid-market assets face weaker rent growth and refinancing options. That is a management thesis, not yet independent evidence of sector-wide divergence.

Near term, strong results may support sentiment, but rates and equity issuance can cap multiple expansion. Over 1–3 months, track closure and funding of pending deals, SHOP same-store performance versus acquired-asset lease-up, and the cost of capital. Over 6–18 months, maturities may expand the acquisition pipeline, while execution and dilution determine whether that pipeline creates value. The contrarian risk is treating reported growth as purely organic: verify per-share cash-flow growth and same-store metrics before extrapolating the headline pace.

Key Decisions for Investors

• Prefer a conditional long WELL over a broad healthcare-REIT exposure only if the share price weakens without deterioration in SHOP operating trends; use VNQ as a broad REIT hedge, recognizing the hedge will not isolate senior-housing risk. Do not chase the earnings reaction without valuation and dilution checks.
• Before adding, verify the pending investment pipeline’s closing pace, equity/OP-unit funding mix, and expected per-share contribution. Treat announced investment volume as optionality, not booked earnings.
• Falsify the operating thesis if SHOP same-store NOI falls below management’s 20.25%–21.75% outlook range, or if expense growth erodes the RevPOR-to-ExpPOR spread. Reassess the acquisition thesis if financing costs rise enough to make lease-up returns unattractive or leverage moves materially above the low-3x range.
• No standalone BKD position from this call: the Brookdale transaction details and its specific earnings or balance-sheet effects are insufficiently established here.